Benefit Expectations and Neuroprotective Prescribing for Acute Ischemic Stroke in China
Preprint
Abstract
Background: Neuroprotective therapies are frequently used for acute ischemic stroke in China. We examined associations of neurologists’ self-rated familiarity, perceived importance, and benefit expectations with reported prescribing frequency. Methods: A hospital-based quota survey recruited attending-level or senior neurologists involved in acute ischemic stroke care across mainland China from May 27 to July 16, 2025. High-frequency use was defined as prescribing neuroprotective therapy to at least 60% of patients. High familiarity and importance were ratings of 4 or 5 on 5-level scales; consistently high benefit expectations required ratings of 4 or 5 in all 4 scenarios. Modified Poisson generalized estimating equations estimated adjusted prevalence ratios (PRs) with hospital-clustered robust standard errors. Results: Among 1982 neurologists from 251 hospitals, 1007 (50.8%) were men and 1745 (88.0%) practiced in tertiary hospitals. High-frequency use was reported by 1596 respondents (80.5%), high familiarity by 1006 (50.8%), and consistently high benefit expectations by 1290 (65.1%). Lower familiarity with high-frequency use was reported by 743 respondents (37.5%). High familiarity (adjusted PR, 1.053; 95% CI, 1.007–1.102), high perceived importance (adjusted PR, 1.294; 95% CI, 1.148–1.458), and consistently high benefit expectations (adjusted PR, 1.198; 95% CI, 1.131–1.269) were associated with high-frequency use after adjustment for demographic and professional characteristics. Conclusions: Frequent self-reported neuroprotective prescribing coexisted with lower self-rated familiarity in a substantial subgroup. Familiarity, perceived importance, and benefit expectations were associated with prescribing frequency. These cross-sectional, class-level measures cannot establish prescribing appropriateness or causality. Studies linking drug-specific observed prescribing to indications and patient outcomes are needed.Keywords
This publication has 14 references indexed in Scilit:
- Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic StrokeJAMA Neurology, 2024
- Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 updateStroke and Vascular Neurology, 2023
- Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic StrokeJAMA Neurology, 2023
- Continuing education meetings and workshops: effects on professional practice and healthcare outcomesCochrane Database of Systematic Reviews, 2021
- StrokeThe Lancet, 2020
- Effect of a Multifaceted Quality Improvement Intervention on Hospital Personnel Adherence to Performance Measures in Patients With Acute Ischemic Stroke in ChinaJAMA, 2018
- Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammationThe Lancet Neurology, 2016
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) StatementEpidemiology, 2007
- A Modified Poisson Regression Approach to Prospective Studies with Binary DataAmerican Journal of Epidemiology, 2004
- Why Don't Physicians Follow Clinical Practice Guidelines?JAMA, 1999